Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay

Reports of in vitro resistance of human immunodeficiency virus type 1 (HIV-1) to zidovudine (AZT) have raised concerns about the development of resistance to other dideoxynucleosides in clinical use. To address this, we have developed a screening assay which supports the growth of clinical isolates and have applied this to a series of paired isolates from patients entered into a phase I trial of didanosine (DDI). Thirteen patients (10 with AIDS, 3 with AIDS-related complex) who had been exposed to AZT for a mean of 6.5 months (range, 1 to 13 months) were treated with DDI at 750 mg/day. Paired isolates were obtained pretherapy and after a mean of 58 weeks (range, 21 to 90) of DDI therapy by coculture of peripheral blood mononuclear leukocytes (PBLs) with phytohemagglutinin-stimulated donor PBLs. Isolates were passaged only one additional time in PBLs and then tested in parallel in a microtiter assay with phytohemagglutinin-stimulated donor PBLs as targets. PBLs were infected with 10(5) 50% tissue culture infectious doses per 10(7) cells and exposed to DDI (1 to 50 microM) or AZT (0.01 to 100 microM), and supernatants were assayed for the HIV p24 antigen at 7 days postinfection. Control AZT-susceptible and resistant isolates were included. The median pre- and posttherapy DDI susceptibilities of the 13 pairs of isolates were 10.0 microM (range, 1 to 25 microM) and 17.5 microM (range, 2.5 to 50 microM), respectively (P = 0.036; Wilcoxon signed-rank test). These studies thus indicated that (i) the susceptibility to DDI tends to mildly decrease with drug exposure; (ii) the susceptibility to AZT improves with time off AZT; (iii) baseline susceptibilities to DDI have a wide range, and the CD4 response may correlate with the initial susceptibility; and (iv) a PBL-based microtiter assay is useful for screening clinical isolated for dideoxynucleoside susceptibility profiles.

[1]  D. Richman,et al.  Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy , 1992, Journal of acquired immune deficiency syndromes.

[2]  E. Walter,et al.  HIV-1 sensitivity to zidovudine and clinical outcome in children , 1992, The Lancet.

[3]  J. Groopman,et al.  Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. , 1991, The American journal of medicine.

[4]  S D Kemp,et al.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.

[5]  G. Shaw,et al.  High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels. , 1991, The Journal of infectious diseases.

[6]  F. Balis,et al.  Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[7]  M. Wainberg,et al.  Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs , 1991, Antimicrobial Agents and Chemotherapy.

[8]  C. Crumpacker,et al.  Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S D Kemp,et al.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. , 1991, AIDS.

[10]  B. Larder,et al.  Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy , 1990, The Lancet.

[11]  M. Beltangady,et al.  Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. , 1990, Reviews of infectious diseases.

[12]  D. Richman,et al.  Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. , 1990, The American journal of medicine.

[13]  D. Richman,et al.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay , 1990, Antimicrobial Agents and Chemotherapy.

[14]  D. McPhee,et al.  Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. , 1990, The Journal of infectious diseases.

[15]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[16]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[17]  K. Gelmon,et al.  Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy , 1989, AIDS.

[18]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[19]  B. Chesebro,et al.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity , 1988, Journal of virology.

[20]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[21]  B. Chesebro,et al.  Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. , 1991, The Journal of infectious diseases.

[22]  S. Lagakos,et al.  Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. , 1990, Journal of acquired immune deficiency syndromes.

[23]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.